An international team of researchers led by Michael E. Belloy, PhD, assistant professor of neurology and of psychiatry at WashU Medicine, identified key genetic targets for potential Alzheimer’s disease therapeutics development. Targeting specific genes in individuals would allow researchers to take a much more precise approach to Alzheimer’s disease prevention and treatment. Their findings were […]
Autosomal dominant Alzheimer’s disease (ADAD) is a form of genetically inherited Alzheimer’s that makes up only about 1% of Alzheimer’s disease occurrences. However, because of the extremely high rate and early age at which individuals with the gene mutations develop Alzheimer’s disease, and also because of the high heritability of the mutation, ADAD is widely […]
With an increasingly aging global population and no available preventative treatments, Alzheimer’s disease and related dementias are poised to become an even larger public health challenge. The mechanisms underlying Alzheimer’s disease are difficult to study because the disease has a long developmental period during which changes in the brain can occur years before symptoms appear. […]
WashU Medicine has been awarded nearly $800,000 by the National Artificial Intelligence Research Resource (NAIRR) Pilot program, an initiative of the National Science Foundation (NSF), and Microsoft to develop AI tools aimed at improving biomedical research efficiency, with an initial focus on Alzheimer’s disease. The grant will fund the Consortium for Biomedical Research and AI […]
On April 8, Washington University School of Medicine in St. Louis recognized investigators who received their first R01 research grants from the National Institutes of Health (NIH). Receiving an R01 grant is an important milestone for scientists who are establishing their careers as independent researchers. Bhooma R. Aravamuthan, MD, DPhil, FAAN, FCNS, assistant professor of […]
The new generation of Alzheimer’s disease drugs — the first proven to change the course of the disease — typically extend independent living for patients by 10 months. Called monoclonal antibodies, they reduce the accumulations of a harmful protein, amyloid, in the brain and require high-dose, once- or twice-monthly infusions of the medication.
A new case report published by David B. Clifford, MD, and colleagues detailed the anti-amyloid therapy treatment course of a patient who developed Alzheimer’s disease concurrently with a pre-existing HIV diagnosis. The patient, who was diagnosed with HIV in 2005, began showing signs of cognitive decline in 2015 and received a clinical diagnosis of Alzheimer’s […]
Older adults who experienced at least one fall exhibited a faster decline in cognitive skills over the following decade than those who hadn’t fallen, according to a new study by researchers at Washington University School of Public Health in St. Louis. The study also revealed that falls are a risk factor for Alzheimer’s disease on […]
Scientists showed in a new study published Thursday that they could use blood draws to build a “clock” for Alzheimer’s disease that could roughly predict whensymptoms will develop, findings that could eventually transform how the illness is diagnosed and treated.
Researchers at Washington University School of Medicine in St. Louis have developed a method to predict when someone is likely to develop symptoms of Alzheimer’s disease using a single blood test. In a new study published Feb. 19 in Nature Medicine, the researchers demonstrated that their models predicted the onset of Alzheimer’s symptoms within a […]